2. Academic Validation
  3. A review on the treatment of multiple myeloma with small molecular agents in the past five years

A review on the treatment of multiple myeloma with small molecular agents in the past five years

  • Eur J Med Chem. 2022 Feb 5:229:114053. doi: 10.1016/j.ejmech.2021.114053.
Zhenzhen Zhang 1,  Xin Liu 2,  Liyun Zhao 1,  Yaru Zhou 1,  Jianyou Shi 3,  Weini Chen 4,  Jinqi Li 5
Affiliations

Affiliations

  • 1 Personalized Drug Therapy Key Laboratory of Sichuan Province, Department of Pharmacy, Sichuan Academy of Medical Science&Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, 610072, Chengdu, China.
  • 2 Department of Laboratory Medicine, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, 610072, Chengdu, China.
  • 3 Personalized Drug Therapy Key Laboratory of Sichuan Province, Department of Pharmacy, Sichuan Academy of Medical Science&Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, 610072, Chengdu, China. Electronic address: shijianyoude@126.com.
  • 4 Department of Radiology, Sichuan Provincial People's Hospital & University of Electronic Science and Technology of China Affiliated Hospital, Chengdu, 610072, China. Electronic address: 16219227@qq.com.
  • 5 Personalized Drug Therapy Key Laboratory of Sichuan Province, Department of Pharmacy, Sichuan Academy of Medical Science&Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, 610072, Chengdu, China. Electronic address: lijinqi2002@126.com.
PMID: 34974338 DOI: 10.1016/j.ejmech.2021.114053
Abstract

Multiple myeloma is currently incurable, and the incidence rate is increasing year by year worldwide. Although in recent years the combined treatment plan based on Proteasome inhibitors and immunomodulatory drugs has greatly improved the treatment effect of multiple myeloma, most patients still relapse and become resistant to current treatments. To solve this problem, scientists are committed to developing drugs with higher specificity, such as iberdomide, which is highly specific to ikaros and aiolos. This review aims to focus on the small molecular agents that are being researched/clinically used for the treatment of multiple myeloma, including the target mechanism, structure-activity relationship and application prospects of small molecular agents.

Keywords

Multiple myeloma; Research overview; Small molecular agents.

Figures
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z